Qpioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol
Amy Peacock, Briony Larance, Michael Farrell, Rose Cairns, Nicholas Buckley, Louisa Degenhardt
BMJ Open | BMJ PUBLISHING GROUP | Published : 2018
Awarded by NHMRC
This work was supported by investigator-initiated untied educational funding from Seqirus Pty Ltd (the marketer of tapentadol SRF in Australia) granted to AP, BL, MF, RC, and LD. BL, AP and LD are supported by NHMRC research fellowships (#1073858, #1109366 and #1041472). The National Drug and Alcohol Research Centre at UNSW Australia is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.